Naloxone Accord (Naloxone Hydrochloride)

Naloxone, the active ingredient in Naloxone Accord, is an opioid antagonist presented as an injection solution for intravenous use. It competitively blocks mu, kappa and delta opioid receptors, rapidly reversing the respiratory and central nervous system depression caused by opioid overdose in emergency medical situations.

GNH USA supplies Naloxone Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this essential emergency antidote. The company adheres to stringent quality standards and offers regulatory‑supported distribution across EU and global markets.

Naloxone is an opioid antagonist used in the management of opioid‑related emergencies.

- Opioid overdose: rapid reversal of life‑threatening respiratory depression. - Opioid‑induced sedation: restores consciousness and normal breathing. - Post‑operative opioid toxicity: counteracts excessive opioid effects after surgery.

Adverse reactions may occur following administration of naloxone injection.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Vomiting: occasional emesis after reversal. - Sweating: increased perspiration during recovery. - Tachycardia: transient elevation of heart rate. - Hypertension: short‑term rise in blood pressure. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Acute opioid withdrawal syndrome: severe agitation, pain, and autonomic instability. - Severe hypertension: marked increase in blood pressure requiring intervention. - Cardiac arrhythmias: irregular heart rhythms, including ventricular tachycardia. - Anaphylaxis: rare systemic allergic reaction with airway compromise.

Naloxone should be used with careful clinical assessment and monitoring.

- Confirm diagnosis: verify opioid overdose before administration. - Monitor vitals: observe respiratory status and blood pressure continuously. - Cardiovascular watch: be alert for hypertension or tachyarrhythmia after reversal. - Pregnancy considerations: use only if the expected benefit outweighs potential risk. - Avoid duplicate antagonists: do not co‑administer other opioid antagonists without medical guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naloxone may interact with other agents that affect opioid pathways or cardiovascular function.

Major Interactions (Avoid): - Concurrent opioid antagonists: may precipitate severe withdrawal. - Beta‑blockers: can mask tachycardia response after naloxone. - Monoamine oxidase inhibitors: theoretical risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Opioid agonists: may require additional naloxone dosing. - Sedatives: additive central nervous system depression after naloxone wears off. - Alcohol: can exacerbate withdrawal symptoms and affect hemodynamics.